Skip to main content
. 2023 Sep 26;44(17):6001–6019. doi: 10.1002/hbm.26491

TABLE 2.

Clinical outcomes.

Clinical measure

M (SD)

Cancer survivors Healthy controls Comparison
VHNSS 163.8 (61.31) 10.2 (10.20) p < .001
GSS 48 (23.29) 5.7 (5.70) p < .001
PROMIS‐29
Anxiety 7.5 (3.95) 4.5 (0.71) p = .047
Depression 8.1 (3.76) 4.3 (0.68) p = .003
Fatigue 13.4 (3.41) 5.2 (1.48) p < .001
Sleep disturbance 12.1 (4.12) 6.6 (1.51) p = .001
Social 12.7 (5.23) 4.3 (1.06) p < .001
Pain 9.9 (5.71) 4.4 (1.35) p = .006
Neurotoxicity 37.8 (24.71) 4.4 (4.35) p < .001
Quality of life 38.3 (11.95) 56.1 (2.89) p < .001
BRIEF
Inhibit 5.82 (1.52) 4.9 (0.88) p = .118
Shift 10.18 (2.41) 6.6 (0.84) p < .001
Emotional control 15.73 (3.88) 11.5 (2.32) p = .004
Initiate 14.55 (4.22) 8.9 (1.37) p < .001
Working memory 14.36 (3.47) 7.5 (0.71) p < .001
Plan/organize 17.82 (4.84) 11.3 (2.45) p < .001
Organization of materials 13.27 (3.09) 10.4 (3.84) p = .097
Task monitor 10.90 (1.52) 6.6 (0.97) p < .001
Self‐monitor 10.18 (1.70) 6.9 (1.60) p < .001

Note: Vanderbilt Head and Neck Symptom Survey Version 2.0 (VHNSS), VHNSS General Symptom Survey (GSS). Values in bold font highlights statistically significant findings.